Evidence map›Paper›PMID 37718324›Full record

ArticleCalcified tissue international2023

Hepatitis C-associated Osteosclerosis (HCAO): Long-Term Follow-Up of a New Case Recovered After Antiviral Treatment.

Gaetano Paride Arcidiacono, Carlo Poci, Stefania Sella, Marco Onofrio Torres, Francesca Zanchetta, Alberta Cecchinato, Martin Diogo, Mor Peleg Falb, Sandro Giannini

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in Calcified tissue international, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Gaetano Paride ArcidiaconoDepartment of Medicine, Clinica Medica 1, University of Padua, Via Giustiniani 2, 35128, Padua, Italy. gaetano.arcidiacono@unipd.it.ORCID http://orcid.org/0000-0003-0409-4449
Carlo PociDepartment of Medicine, Clinica Medica 1, University of Padua, Via Giustiniani 2, 35128, Padua, Italy.
Stefania SellaDepartment of Medicine, Clinica Medica 1, University of Padua, Via Giustiniani 2, 35128, Padua, Italy.
Marco Onofrio TorresDepartment of Medicine, Clinica Medica 1, University of Padua, Via Giustiniani 2, 35128, Padua, Italy.
Francesca ZanchettaDepartment of Medicine, Clinica Medica 1, University of Padua, Via Giustiniani 2, 35128, Padua, Italy.
Alberta CecchinatoDepartment of Medicine, Clinica Medica 1, University of Padua, Via Giustiniani 2, 35128, Padua, Italy.
Martin DiogoDepartment of Medicine, Clinica Medica 1, University of Padua, Via Giustiniani 2, 35128, Padua, Italy.
Mor Peleg FalbDepartment of Medicine, Clinica Medica 1, University of Padua, Via Giustiniani 2, 35128, Padua, Italy.
Sandro GianniniDepartment of Medicine, Clinica Medica 1, University of Padua, Via Giustiniani 2, 35128, Padua, Italy.
University of Padua · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatitis C-associated osteosclerosis (HCAO) is a very rare condition that can be observed in a small number of patients with Hepatitis C Virus (HCV) infection. HCAO is usually characterized by widespread bone sclerosis, associated with severe bone pain, and increased levels of bone turnover markers, especially alkaline phosphatase (ALP). In this report, we present the case of a 55-year-old woman who was affected by HCV and came to our attention for severe and diffuse bone pain. Radiological studies showed bone sclerosis, and bone mineral density (BMD) was markedly increased, as well as serum ALP levels. The patient was initially treated with intravenous pamidronate, which provided only a transient benefit on clinical symptoms. Then antiviral therapy for HCV (interferon-alfa and ribavirin) was started and it was effective in making the viral load undetectable. After a long follow-up period, we observed a persistent remission of bone pain, a reduction in BMD together with a progressive trend toward the normalization of bone turnover markers. In conclusion, HCAO, although rare, should be considered among the potential causes of increased bone mass in patients with HCV infection, and treatment for the underlying infection may be effective in controlling the manifestations of this disease.

Indexed as

Hepatitis COsteosclerosisAntiviral AgentsFemaleFollow-Up StudiesHepacivirusHumansMiddle AgedPainSclerosisAntiviral AgentsHCAOHCVHepatitis C virusOsteosclerosis

Identifiers

PMID37718324
OpenAlexW4386812049

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.